Effect of Genzyme's multiple sclerosis treatment Lemtrada (alemtuzumab) on slowing brain atrophy and MRI lesion activity maintained through four years

Genzyme, a Sanofi company, has announced new magnetic resonance imaging (MRI) data from the Lemtrada® (alemtuzumab) clinical development program at the 67th American Academy of Neurology (AAN) Annual Meeting.

In relapsing remitting multiple sclerosis (RRMS)patients treated with Lemtrada in the Phase III pivotal studies, MRI effects observed in the two-year trials were maintained through two additional years in the extension study (years three and four). After the initial two courses of treatment in the pivotal studies, which were given at month zero and at month 12, approximately…

Favicon of www.medicalnewstoday.com da : www.medicalnewstoday.com

Prosegui la lettura...
Traduci l'articolo...

Sclerosi Multipla News

Potrebbe interessarti anche

Argomenti correlati